Precipio Inc (PRPO)
Official siteHEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ
Market Cap: $39.68M
Last updated: Nov 17, 2026 at 11:06 AM ET
Precipio Inc (PRPO) Competitors
The companies most similar to Precipio are Insight Molecular Diagnostics (IMDX), MDxHealth SA (MDXH) and Exagen (XGN). By market cap, Precipio ranks 8th of the 13 companies on this page; Revvity (RVTY) is the largest at $17.24B.
Peer Comparison
PRPO's ROIC of -5.7% is above the peer median of -29.5%, and its revenue growth of 8.3% is above the median of 0.0%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Precipio (PRPO) | $39.68M | N/A | 1.3x | -4.1% | -5.7% | 8.3% | 0.00% |
| Insight Molecular Diagnostics Inc. (IMDX) | $70.03M | N/A | 40.9x | 0.0% | 197.8% | -53.9% | 0.00% |
| MDxHealth SA (MDXH) | $13.75M | N/A | N/A | -38.3% | -40.5% | -17.2% | 0.00% |
| Exagen Inc (XGN) | $105.37M | N/A | 1.3x | -25.1% | -40.4% | 6.8% | 0.00% |
| Personalis Inc (PSNL) | $1.70B | N/A | 20.9x | -147.7% | N/A | 76.6% | 0.00% |
| Quince Therapeutics, Inc. (QNCX) | $32.27M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Myriad Genetics Inc (MYGN) | $542.92M | N/A | 0.7x | -16.1% | -29.5% | -1.5% | 0.00% |
| Revvity Inc. (RVTY) | $17.24B | 26.8x | 5.6x | 8.6% | 3.4% | 4.3% | 0.19% |
| NextCure Inc (NXTC) | $29.31M | N/A | N/A | 0.0% | N/A | -100.0% | 0.00% |
| Plus Therapeutics Inc (PSTV) | $26.64M | N/A | 2.0x | -230.2% | -827.8% | -2.9% | 0.00% |
| Instil Bio Inc. (TIL) | $41.23M | N/A | N/A | 0.0% | -11.9% | 0.0% | 0.00% |
| Veru Inc (VERU) | $35.64M | N/A | N/A | 0.0% | N/A | 18.3% | 0.00% |
| CareDx Inc (CDNA) | $4.09B | 48.2x | 6.4x | 25.9% | N/A | 39.3% | 0.00% |
| Peer median | $55.63M | 37.5x | 5.6x | 0.0% | -29.5% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to Precipio, ranked by how closely their business, size, sector and industry match. The largest group, 7 of the 12, is in Diagnostics & Research; the other 5 are in Biotechnology.
| Company | About | Peers |
|---|---|---|
| Insight Molecular Diagnostics Inc. (IMDX)Diagnostics & Research | OncoCyte Corporation is a precision diagnostics company in the United States and internationally. The company is headquartered in Irvine, California. | IMDX competitors |
| MDxHealth SA (MDXH)Diagnostics & Research | MDxHealth SA is a prominent biotechnology company focused on precision diagnostics that enhance cancer management, particularly in prostate and bladder cancers. | MDXH competitors |
| Exagen Inc (XGN)Diagnostics & Research | Exagen Inc. develops and markets various test products based on its Cell-Bound Complement Activation Products technology under the AVISE brand name... | XGN competitors |
| Personalis Inc (PSNL)Diagnostics & Research | Personalis, Inc. is a global cancer genomics company. The company is headquartered in Menlo Park, California. | PSNL competitors |
| Quince Therapeutics, Inc. (QNCX)Biotechnology | Quince Therapeutics, Inc., a biopharmaceutical company, is focused on advancing precision therapies for rare and debilitating diseases. | |
| Myriad Genetics Inc (MYGN)Diagnostics & Research | Myriad Genetics, Inc., a molecular diagnostics company, develops and markets predictive, personalized... | MYGN competitors |
| Revvity Inc. (RVTY)Diagnostics & Research | Revvity, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets globally. | RVTY competitors |
| NextCure Inc (NXTC)Biotechnology | NextCure, Inc., a clinical-stage biopharmaceutical company, is dedicated to the discovery and development of novel immunomedicines to treat cancer and other... | NXTC competitors |
| Plus Therapeutics Inc (PSTV)Biotechnology | Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacturing... | PSTV competitors |
| Instil Bio Inc. (TIL)Biotechnology | Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer patients. | TIL competitors |
| Veru Inc (VERU)Biotechnology | Veru Inc., an oncology biopharmaceutical company, focuses on the development of drugs for the treatment of cancers. | VERU competitors |
| CareDx Inc (CDNA)Diagnostics & Research | CareDx, Inc. discovers, develops and markets diagnostic solutions for transplant patients and caregivers globally. | CDNA competitors |
Frequently Asked Questions About PRPO
Who are Precipio's main competitors?
The companies most similar to Precipio include Insight Molecular Diagnostics (IMDX), MDxHealth SA (MDXH), Exagen (XGN), Personalis (PSNL) and Quince Therapeutics (QNCX), listed from the closest match.
Who is Precipio's biggest competitor?
Revvity (RVTY) is the largest of the similar companies at $17.24B; Insight Molecular Diagnostics (IMDX) is the closest match by business profile, size, sector and industry.
How does PRPO stock compare with its competitors?
PRPO's P/S is 1.3x against a peer median of 5.6x; its net margin is -4.1% against a peer median of 0.0%.
Which of Precipio's competitors pays a higher dividend?
Precipio pays no dividend. Revvity (RVTY) has a higher forward dividend yield; Revvity (RVTY) has the highest at 0.19%.
Is Precipio bigger than its competitors?
No. Precipio is 8th by market cap among the 13 companies on this page; the largest is Revvity (RVTY) at $17.24B.
PRPO pages: Overview, Earnings, Financials, Valuation, Competitors